The present invention relates to high-titer hybrid vims vectors which produce virus-like vesicle (VLVs) and compositions and methods thereof for targeting a malignancy or infectious disease. VLVs are a capsid-free, self-replicating artificial virus platform carrying positive-strand capped and polyadenylated RNA encoding an in vitro evolved Semliki Forest vims (SFV) RNA-dependent RNA replicase and the vesicular stomatitis virus (VSV) glycoprotein. The VLVs of the present invention and pharmaceutical compositions thereof encode for polynucleotide and/or polypeptide therapeutic agents useful in methods for the treatment, prophylaxis, and prevention of malignancies and infectious diseases.

Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.

Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.

The present invention belongs to the field of biomedicine and relates to use of VCP (valosin-containing protein, VCP) inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that VCP inhibitor can be used in the preparation of an anti-tumor synergist for oncolytic virus. Meanwhile, the present invention relates to a pharmaceutical composition comprising VCP inhibitor and oncolytic virus, a pharmaceutical kit comprising VCP inhibitor and oncolytic virus, and use of VCP inhibitor and oncolytic virus for treating tumor, especially a tumor that is not sensitive to oncolytic virus. The present invention also relates to an anti-tumor administration system, characterized in that, comprising oncolytic virus and a reagent for detecting the expression level of VCP.

The present disclosure relates to synthetic oncolytic viruses comprising a lipid nanoparticle comprising one or more types of lipid and a self-amplifying replicon RNA comprising a sequence that encodes an immunomodulatory molecule.

Use of a proteasome inhibitor and an alphavirus in the preparation of an anti-tumor medicament. The proteasome inhibitor can be used to prepare an alphavirus anti-tumor synergist. A pharmaceutical composition comprising a proteasome inhibitor and an alphavirus, including a pharmaceutical kit comprising the proteasome inhibitor and the alphavirus, and use of the proteasome inhibitor and the virus in the treatment of tumors, particularly tumors insensitive to the alphavirus.

Provided are polynucleotides and viral vectors, particularly, Alphavirus vectors such as Sindbis viral vectors, which encode an immune checkpoint protein, or a ligand binding portion of the checkpoint protein, or an immune checkpoint protein or ligand binding portion thereof fused to one or more immunoglobulin (Ig) domains, e.g., an Ig hinge region and an Ig heavy chain constant domain. Methods of treating a mammalian subject having a cancer or tumor are provided, in which the viral vectors, e.g., a Sindbis virus vector, encoding the immune checkpoint protein, a ligand binding portion thereof, or a checkpoint protein fusion protein as described, are administered to the subject, resulting in an anti-cancer or anti-tumor immune response, significant reduction in tumor growth in the treated subject and increased survivability.

Disclosed is the use of a mevalonate metabolic pathway inhibitor and an alphavirus in preparing an anti-tumor drug. The mevalonate metabolic pathway inhibitor can be used in preparing an alphavirus anti-tumor synergist. Disclosed are a pharmaceutical composition containing the mevalonate metabolic pathway inhibitor and the alphavirus, a drug kit containing the mevalonate metabolic pathway inhibitor and the alphavirus, and the use of the mevalonate metabolic pathway inhibitor and the alphavirus in treating tumors, especially those that are insensitive to the alphavirus.

The present disclosure relates to synthetic oncolytic viruses comprising a lipid nanoparticle comprising one or more types of lipid and a self-amplifying replicon RNA comprising a sequence that encodes an immunomodulatory molecule.

Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.